Advertisement

Topics

Companies Related to "Effects of CPAP Treatment of OSA in Patients With Heart Failure" [Most Relevant Company Matches] RSS

04:39 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Effects of CPAP Treatment of OSA in Patients With Heart Failure" found in our extensive corporate database of over 50,000 company records.

Showing "Effects CPAP Treatment Patients With Heart Failure" Companies 1–25 of 6,800+

Extremely Relevant

Ancora Heart Inc.

Ancora Heart, Inc., based in Santa Clara, Calif., is dedicated to helping people with heart failure feel better and live longer. Ancora Heart developed the AccuCinch System, an investigational therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure. The AccuCinch heart failure treatment was created to benefit ...


Ancora Heart, Inc.

Ancora Heart, Inc., based in Santa Clara, Calif., is dedicated to helping people with heart failure feel better and live longer. Ancora Heart developed the AccuCinch System, an investigational therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure. The AccuCinch heart failure treatment was created to benefit ...

The Heart Failure Society of America

Heart failure is a progressive condition in which the heart muscle becomes abnormal after damage from heart attack or high blood pressure and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in th...


Texas Heart Institute

The Texas Heart Institute (www.texasheart.org), founded by world-renowned cardiovascular surgeon Dr. Denton A. Cooley in 1962, is a nonprofit organization dedicated to reducing the devastating toll of cardiovascular disease through innovative and progressive programs in research, education and improved patient care. Together with its clinical partner, St. ...

Sunshine Heart

Heart failure is a common condition in which the heart becomes unable to pump sufficient blood to meet the body's needs. Over five million people in the United States have heart failure and it results in over 300,000 deaths each year. Heart failure is a progressive condition and typically results from damage to the heart muscle arising from a heart attack or virus.

Terumo Heart Inc.

More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization. The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transpla...

DC Devices, Inc.

DC Devices, Inc. is dedicated to revolutionizing the treatment of heart failure with first-in-class structural heart devices. The company has developed the world’s first transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). The InterAtrial Shunt Device (IASD™) S...

3F Therapeutics, Inc

3F Therapeutics, Inc. was formed in late 1998 to develop, manufacture, and market innovative cardiovascular devices for patients with currently unmet clinical needs. The Company’s products are intended to significantly improve upon the performance of heart valves presently in the market and to address the resultant complications of patients with congestive heart failure. At present, over 260,000...

Heart Failure Society of America, Inc.

The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The Mission of HFSA is to: Promote research related to all aspects of heart failure and to provide a forum for presentation of ba...

Celladon Corporation

Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company’s products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium ...

CircuLite®, Inc.

CircuLite is developing disruptive solutions to improve the treatment of chronic heart failure. The Company’s minimally invasive circulatory support systems are intended to work in conjunction with the heart to enhance clinical outcomes and improve quality of life for patients and their families. Synergy®, currently in a CE Mark clinical trial, fea...

Relevant

Celladon Corp.

Celladon Corp., based in La Jolla, Calif., was launched in October 2004 as a privately held biotechnology company with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company's products target calcium cycling and contractility deficit in heart muscle cells. In addition to MYDICAR®, Celladon is developing traditional small molecule activato...

SynCardia Systems, LLC

SynCardia Systems, LLC (www.syncardia.com) in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a brid...

ORQIS Medical Corporation

ORQIS Medical Corporation is a privately held, medical device company developing its discovery of a novel approach to treat the underlying mechanisms responsible for congestive heart failure. ORQIS Medical discovered that continuous aortic flow augmentation (CAFA), blood flow augmentation specifically in the descending aorta, may correct abnormal circulatory conditions associated with heart failur...

NitroMed

NitroMed, Inc. of Lexington, Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil, an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as ACE inhibitors and/or beta blockers. BiDil was approved b...

Intercure, Inc.

InterCure, a medical device company has developed and patented a technology platform for respiratory-based treatment of cardiovascular and pulmonary diseases. The Company has incorporated its "Interactive Respiratory-Pacing" technology platform into several product lines, the first two of which offer a new therapeutic class of non-drug treatments for two of the most widespread and costly disease s...

Acorn Cardiovascular

Acorn Cardiovascular™ is a privately held medical device company that was incorporated in 1996 and is located in St. Paul, Minnesota, USA. Mission: Acorn Cardiovascular develops innovative solutions to successfully treat patients with heart failure and restore hope for a better, longer life. Background: Heart failure (HF) is a condition that is caused by damage to the heart muscle, which re...

ARCA biopharma, Inc.

ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company's lead product candidate, bucindolol hydrochloride, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that i...

CardioKine, Inc.

CardioKine is a specialty pharmaceutical company developing innovative compounds for the treatment and prevention of heart failure and related cardiovascular indications.Heart failure is one of the world’s fastest growing diseases, impacting all segments of society. It occurs when the heart becomes too weak to pump blood, leading to accumulation of fluids, shortness of breath and premature death...

SinuSys Corp.

Chronic sinusitis affects more than 31 million people in the United States. It is more prevalent than heart disease and asthma, and has a greater impact on patients’ quality of life than chronic back pain or congestive heart failure. The U.S. healthcare system currently spends more than $8 billion annually on improving the health of patients with sinu...

CircuLite

CircuLite® is transforming heart failure treatment with the development of minimally invasive devices for long-term partial circulatory support (PCS). By enabling a proactive and lower-risk treatment approach by supplementing a patient’s native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart ...

NanoCor Therapeutics, Inc.

NanoCor Therapeutics, Inc. ("NanoCor") is a biotechnology company founded to create the first viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure ("CHF"). The company was spun off from Asklepios BioPharmaceutical, Inc. in August 2005.CHF is the end product of a number of cardiovascular diseases that degrade the heart's ability to pump blood efficiently. The Ame...

Sunshine Heart, Inc.

Sunshine Heart (ASX:SHC) is a global medical device company committed to novel cardiac and coronary therapy. The company is currently developing the C-Pulse® Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-...

BMI

BMI was established in the summer of 2004 with a strong portfolio of early stage innovations transferred from Medinnova and from Oslo Research Park. Today, BMI is focusing on the development of drugs based on compounds that interfere with the signal mediator serotonin. In particular, BMI is currently in clinical phase II with GSK's 5-HT4 antagonist piboserod for the treatment of heart failure. D...

IPS HEART

IPS HEART is a privately-held biopharmaceutical company dedicated to addressing heart attack, heart failure and duchenne cardiomyopathy via next generation cellular therapy. IPS HEART was the first company to exclusively focus on induced pluripotent stem cells and heart disease. IPS HEART is a resident at Johnson & Johnson Innovation, JLABS at TMC in the T...


More From BioPortfolio on "Effects of CPAP Treatment of OSA in Patients With Heart Failure"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks